Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Mecbotamab Vedotin
Synonyms
Therapy Description

Mecbotamab Vedotin is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mecbotamab Vedotin BA3011|CAB-AXL-ADC|BA-3011|BA 3011 AXL Antibody 5 Mecbotamab Vedotin is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03425279 Phase Ib/II Mecbotamab Vedotin CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting USA 2
NCT04681131 Phase II Mecbotamab Vedotin Mecbotamab Vedotin + unspecified PD-1 antibody CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC Active, not recruiting USA | POL | ITA | GRC | ESP 2


Additional content available in CKB BOOST